Log in

CNBX CNBX Pharmaceuticals Inc. OTC · United States

CNBX Pharmaceuticals (CNBX) news

Top story · Oct 1, 2026 · SEC filing 8-K

CNBX Pharmaceuticals changes its auditor

On the same date, the Board of Directors of the Company engaged Vilki & Co-#1 Luxor Palace, Gandhi Smruti Bhavan, Gujarat, India 394651 (the “New Accounting Firm”) as its new independent accounting firm as of and for the year ended August 31 st , 2026.

Source: 8-K filed Oct 1, 2026 on SEC EDGAR

Latest CNBX Pharmaceuticals news

We have not published a story on CNBX Pharmaceuticals yet. When there is news, it will appear here.

CNBX Pharmaceuticals annual financials

LineFY ended Aug 31, 2025FY ended Aug 31, 2024
Revenue$0$130,074
Research and development$0$194,788
Net income (loss)-$313,976-$695,198
Cash from operations-$171,305-$244,269
Cash and equivalents$15,111$26,416

Latest balance sheet, May 31, 2026 (10-Q): cash and equivalents $9,487.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about CNBX Pharmaceuticals

What is the ticker symbol of CNBX Pharmaceuticals?

CNBX Pharmaceuticals Inc. trades under the ticker CNBX on OTC.

Where is CNBX Pharmaceuticals listed?

CNBX Pharmaceuticals Inc. is listed on OTC.

What is the SEC CIK of CNBX Pharmaceuticals?

The SEC Central Index Key (CIK) for CNBX Pharmaceuticals Inc. is 1343009. Its filings are on SEC EDGAR.

How many shares does CNBX Pharmaceuticals have outstanding?

1,605,768,095 shares as of 2026-06-17, per the cover page of its 10-Q filed 2026-06-24.

Which country or territory is CNBX Pharmaceuticals listed under?

Our directory records CNBX Pharmaceuticals Inc. under United States.

What does CNBX Pharmaceuticals do?

Our directory classifies CNBX Pharmaceuticals Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of CNBX Pharmaceuticals?

The ISIN recorded for CNBX Pharmaceuticals Inc. is US13764M2098.

Does aibio.space cover CNBX Pharmaceuticals?

aibio.space lists CNBX Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is CNBX Pharmaceuticals incorporated?

SEC records list its state or country of incorporation as NV.

What was CNBX Pharmaceuticals's revenue last year?

$0 for the fiscal year ended Aug 31, 2025, as reported to the SEC.

Is CNBX Pharmaceuticals profitable?

CNBX Pharmaceuticals Inc. reported a net loss of $313,976 for the fiscal year ended Aug 31, 2025, and used $171,305 of cash in operations, per its annual report to the SEC.

How much does CNBX Pharmaceuticals spend on research and development?

$0 in the fiscal year ended Aug 31, 2025, per its annual report.

How much cash does CNBX Pharmaceuticals have?

$9,487 in cash at May 31, 2026, per its 10-Q.

What is CNBX Pharmaceuticals's market cap?

We do not publish live share prices. In its annual report, CNBX Pharmaceuticals Inc. put the market value of shares held by non-affiliates (public float) at $251,840 as of Aug 31, 2025.

Is CNBX Pharmaceuticals a smaller reporting company?

SEC records list CNBX Pharmaceuticals Inc.'s filer category as: <br>Emerging growth company.

Investor discussion: CNBX Pharmaceuticals

Members talk about CNBX Pharmaceuticals (CNBX). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at CNBX Pharmaceuticals, newest first. Each line links the filing it comes from.

  1. Legal

    Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source

  2. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source

  3. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:CNBX on TradingView.

SEC filings and registration

SEC name
CNBX Pharmaceuticals Inc.
CIK
1343009
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
CNBX (OTC)
State or country of incorporation
NV
Fiscal year ends
August 31
Filer category
<br>Emerging growth company
Business address
#3 BETHESDA METRO CENTER, BETHESDA, MD, 20814
Phone
877-424-2429
Shares outstanding
1,605,768,095 as of 2026-06-17 (10-Q filed 2026-06-24)
Former names
Cannabics Pharmaceuticals Inc.; American Mining Corp; Thrust Energy Corp.

Recent filings (8-K and 6-K are the company's own announcements)

  • 8-K filed 2026-10-01
  • 10-Q filed 2026-06-24
  • 10-Q filed 2026-04-14
  • 8-K filed 2026-03-17
  • 10-Q filed 2026-01-14
  • 10-K filed 2025-12-01
  • 10-Q filed 2025-07-14
  • 10-Q filed 2025-04-14

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

CNBX Pharmaceuticals Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker CNBX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
CNBX Pharmaceuticals Inc.
Ticker
CNBX
Listing
OTC
Country or territory
United States
Business scope
Biotechnology
ISIN
US13764M2098
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.